$622 Million is the total value of COMMODORE CAPITAL LP's 30 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COGT | Sell | COGENT BIOSCIENCES INC | $64,454,000 | +44.5% | 4,319,940 | -12.6% | 10.36% | +9.9% |
| XENE | XENON PHARMACEUTICALS INC | $57,577,000 | +18.7% | 1,594,932 | 0.0% | 9.26% | -9.7% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $55,302,000 | +191.7% | 2,696,340 | +64.6% | 8.89% | +121.9% |
| BLU | Buy | BELLUS HEALTH INC NEW | $54,158,000 | +30.8% | 5,128,557 | +14.5% | 8.71% | -0.5% |
| MRUS | MERUS N V | $52,394,000 | -11.5% | 2,615,762 | 0.0% | 8.42% | -32.7% | |
| CYTK | CYTOKINETICS INC | $43,297,000 | +23.3% | 893,646 | 0.0% | 6.96% | -6.2% | |
| ACRS | ACLARIS THERAPEUTICS INC | $37,943,000 | +12.8% | 2,410,622 | 0.0% | 6.10% | -14.3% | |
| AKRO | New | AKERO THERAPEUTICS INC | $25,315,000 | – | 743,472 | +100.0% | 4.07% | – |
| STSA | SATSUMA PHARMACEUTICALS INC | $22,268,000 | +44.9% | 3,711,286 | 0.0% | 3.58% | +10.2% | |
| TCDA | Sell | TRICIDA INC | $20,702,000 | +5.4% | 1,975,403 | -2.6% | 3.33% | -19.8% |
| CBAY | CYMABAY THERAPEUTICS INC | $20,085,000 | +18.6% | 5,738,500 | 0.0% | 3.23% | -9.8% | |
| New | THIRD HARMONIC BIO INC | $19,322,000 | – | 1,018,569 | +100.0% | 3.11% | – | |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $17,737,000 | – | 738,110 | +100.0% | 2.85% | – |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $15,146,000 | +4.3% | 538,812 | 0.0% | 2.44% | -20.7% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $14,815,000 | +11.9% | 739,661 | 0.0% | 2.38% | -14.9% | |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $13,355,000 | +21.4% | 404,078 | +29.3% | 2.15% | -7.7% |
| KURA | Sell | KURA ONCOLOGY INC | $12,286,000 | -63.3% | 899,407 | -50.8% | 1.98% | -72.1% |
| ABOS | New | ACUMEN PHARMACEUTICALS INC | $11,033,000 | – | 1,100,000 | +100.0% | 1.77% | – |
| KPTI | KARYOPHARM THERAPEUTICS INC | $10,568,000 | +21.1% | 1,935,609 | 0.0% | 1.70% | -8.0% | |
| ALLK | New | ALLAKOS INC | $10,058,000 | – | 1,643,500 | +100.0% | 1.62% | – |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $9,540,000 | – | 1,325,000 | +100.0% | 1.53% | – |
| CELC | CELCUITY INC | $9,241,000 | +10.3% | 920,464 | 0.0% | 1.49% | -16.1% | |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $5,368,000 | – | 103,494 | +100.0% | 0.86% | – |
| KALV | KALVISTA PHARMACEUTICALS INC | $4,535,000 | +47.4% | 312,553 | 0.0% | 0.73% | +12.2% | |
| RZLT | REZOLUTE INC | $3,315,000 | -15.2% | 1,210,000 | 0.0% | 0.53% | -35.5% | |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $3,132,000 | – | 467,468 | +100.0% | 0.50% | – |
| IMUX | IMMUNIC INC | $2,822,000 | -8.9% | 893,013 | 0.0% | 0.45% | -30.7% | |
| BLSA | BCLS ACQUISITION CORP | $2,505,000 | +1.2% | 250,000 | 0.0% | 0.40% | -22.9% | |
| LRMR | New | LARIMAR THERAPEUTICS INC | $2,400,000 | – | 750,000 | +100.0% | 0.39% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $1,213,000 | – | 205,870 | +100.0% | 0.20% | – |
| IVA | Exit | INVENTIVA SAads | $0 | – | -175,500 | -100.0% | -0.21% | – |
| Exit | TENAYA THERAPEUTICS INC | $0 | – | -357,699 | -100.0% | -0.43% | – | |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -13,049,079 | -100.0% | -2.43% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -2,409,961 | -100.0% | -4.90% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.